【摘要】：血管生成(Angiogenesis)是指從已有的血管中發(fā)芽生成新血管的過程,腫瘤的生長、侵襲和轉(zhuǎn)移依賴于新生血管的形成。抑制腫瘤介導的血管生成,阻斷癌細胞的營養(yǎng)途徑,就可以有效抑制癌細胞增殖。血管內(nèi)皮生長因子(Vascular endothelial growth factor, VEGF)是腫瘤新生血管形成中的關(guān)鍵性促血管生長因子,可在體內(nèi)誘導血管新生。目前已經(jīng)得到公認,VEGF對內(nèi)皮細胞的分化、增殖作用是由血管內(nèi)皮生長因子受體-2(Vascular endothelial growth factor receptor-2, VEGFR-2)介導的。因此,在抗腫瘤藥物研發(fā)中,針對VEGFR-2的酪氨酸激酶是一個關(guān)鍵的藥物作用靶點,VEGFR-2酪氨酸激酶抑制劑也成為了抗腫瘤藥物研究的一個重要方向。 本研究的目的是合成各種新型吲哚-苯并咪唑類衍生物,通過篩選獲得具有一定活性和自主知識產(chǎn)權(quán)的化合物,用于進一步的活性研究。本研究主要進行了以下方面的工作： 1對已設(shè)計出的一系列結(jié)構(gòu)新穎、未見報導的新型VEGFR-2酪氨酸激酶抑制劑進行逆合成路線分析,根據(jù)反應(yīng)可行性、路線復雜性、操作安全性等,針對每個化合物的結(jié)構(gòu)設(shè)計出盡可能合理可行的合成路線。 2根據(jù)設(shè)計出的合成路線,對每種化合物進行合成。通過不同的合成路線分別合成了吲哚-3-甲酸、吲哚-3-乙酸、吲哚-3-丙酸、2-吲哚酮-3-丙酸、2-甲基吲哚-3-乙酸和5-甲氧基-2-甲基吲哚-3-乙酸等吲哚酸類化合物。 3合成的這幾種吲哚酸再分別與鄰苯二胺鹽酸鹽、4-甲基鄰苯二胺和3,4-二氨基苯甲酸乙酯在多聚磷酸的催化下發(fā)生脫水環(huán)合反應(yīng),生成九種目標產(chǎn)物吲哚-苯并咪唑類衍生物。 4由(R)-3-喹核醇經(jīng)酯交換法和乙酸酐法兩種方法合成了(R)-3-乙酸奎寧環(huán)基酯,并比較得知,乙酸酐法操作簡單、收率高。
[Abstract]:Angiogenesis (Angiogenesis) is the process of sprouting new blood vessels from existing vessels. Tumor growth, invasion and metastasis depend on the formation of neovascularization. Inhibition of tumor-mediated angiogenesis, blocking the nutritional pathway of cancer cells, can effectively inhibit the proliferation of cancer cells. Vascular endothelial growth factor (Vascular endothelial growth factor, VEGF) is a key angiogenic factor in tumor angiogenesis, which can induce angiogenesis in vivo. It has been recognized that the differentiation and proliferation of endothelial cells by VEGF is mediated by vascular endothelial growth factor receptor-2 (Vascular endothelial growth factor receptor-2, VEGFR-2. Therefore, tyrosine kinase targeting VEGFR-2 is a key drug target in the research and development of antitumor drugs. VEGFR-2 tyrosine kinase inhibitor has also become an important research direction of antitumor drugs. The aim of this study was to synthesize various new indole-benzimidazole derivatives and obtain compounds with certain activity and independent intellectual property rights for further study. The main work of this study is as follows: 1 A series of novel VEGFR-2 tyrosine kinase inhibitors that have been designed have been studied by reverse synthesis route analysis, according to the feasibility of the reaction and the complexity of the route, a series of novel VEGFR-2 tyrosine kinase inhibitors have been designed. According to the structure of each compound, the synthetic route is designed as reasonable and feasible as possible. 2 according to the designed synthetic route, each compound is synthesized. Indole-3-formic acid, indole-3-acetic acid, indole-3-propionic acid, 2-indole-3-propionic acid were synthesized by different synthetic routes. 2-methylindole-3-acetic acid and 5-methoxy-2-methyl-indole-3-acetic acid and other indoleic acid compounds. (3) the synthesized indoleic acid reacts with o-phenylenediamine hydrochloride, 4-methyl-o-phenylenediamine, and ethyl 3o 4-diaminobenzoate respectively under the catalysis of polyphosphoric acid. Nine target products of indole-benzimidazole derivatives were obtained. 4 (R) 3-quinine cycloester was synthesized by transesterification method and acetic anhydride method from (R) 3-quinolinol. It was found that the acetic anhydride method was simple and the yield was high.
【學位授予單位】：青島科技大學
【學位級別】：碩士
【學位授予年份】：2014
【分類號】：R914.5

【參考文獻】

相關(guān)期刊論文 前10條

1 鮑健,陳振東;新型腫瘤治療藥物——酪氨酸激酶抑制劑[J];安徽醫(yī)藥;2004年01期

2 陳燕;李金升;孟慶軍;王瑞;喬保平;魏金星;文建國;;索利那新治療膀胱過度活動癥4周療效分析[J];第三軍醫(yī)大學學報;2011年01期

3 李外 ,古今 ,劉萍;琥珀酸索非那新投放美國市場用于膀胱過度活動癥[J];國外醫(yī)學.藥學分冊;2005年03期

4 史一鳴;鈕因堯;陸陽;;M受體及相關(guān)選擇性藥物研究進展[J];國際藥學研究雜志;2009年05期

5 陳素琴;黃向紅;;吲哚-3-甲醛的合成方法比較研究[J];化工技術(shù)與開發(fā);2009年05期

6 李占成;金云舟;高博;;5-取代吲哚-2-酮的合成[J];合成化學;2012年01期

7 董縉;姚碩蔚;徐云根;;腫瘤血管生成抑制劑[J];化學進展;2010年10期

8 李寧;康從民;呂英濤;;M受體拮抗劑的研究進展[J];化學通報;2008年12期

9 安康;柴曉杰;薛飛;王媛;張婷;;VEGFR-2與抑制劑Sunitinib的分子對接及分子動力學研究[J];化學學報;2012年10期

10 吳明書,張想竹,張繼昌;5-氯-吲哚-2-酮的合成[J];精細化工;2001年04期

，

本文編號：2356806